Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
L ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
L04 IMMUNOSUPPRESSANTS
L04A IMMUNOSUPPRESSANTS
L04AF Janus-associated kinase (JAK) inhibitors
L04AF03 Upadacitinib
D11048 Upadacitinib hydrate (JAN) <JP/US>
USP drug classification [BR:br08302]
Immunological Agents
Immunological Agents, Other
JAK Inhibitors
Upadacitinib
D11048 Upadacitinib hydrate (JAN)
Therapeutic category of drugs in Japan [BR:br08301]
3 Agents affecting metabolism
39 Other agents affecting metabolism
399 Miscellaneous
3999 Others
D11048 Upadacitinib hydrate (JAN)
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG02829 Upadacitinib
D11048 Upadacitinib hydrate
Dermatological agent
DG03243 Atopic dermatitis agent
D11048 Upadacitinib hydrate
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02829 Upadacitinib
D11048 Upadacitinib hydrate
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02829 Upadacitinib
D11048 Upadacitinib hydrate
Drug classes [BR:br08332]
Immunological agent
DG02020 JAK inhibitor
D11048 Upadacitinib hydrate
Antirheumatic agent
DG01985 Disease modifying anti-rheumatic drug (DMARD)
D11048 Upadacitinib hydrate
Dermatological agent
DG03243 Atopic dermatitis agent
D11048 Upadacitinib hydrate
Target-based classification of drugs [BR:br08310]
Protein kinases
Non-receptor tyrosine kinases
JAK family
JAK1
D11048 Upadacitinib hydrate (JAN) <JP/US>
New drug approvals in the USA [br08319.html]
New molecular entities and new therapeutic biological products
D11048
New drug approvals in Europe [br08329.html]
European public assessment reports (EPAR) authorised medicine
D11048
New drug approvals in Japan [br08318.html]
Drugs with new active ingredients
D11048
New drug approvals in the USA, Europe and Japan [br08328.html]
Approval dates by FDA, EMA and PMDA
D11048
Drug metabolizing enzymes and transporters [br08309.html]
Drug metabolizing enzymes
D11048
Drug groups [BR:br08330]
Anti-inflammatory
DG01985 Disease modifying anti-rheumatic drug (DMARD)
DG02020 JAK inhibitor
DG02829 Upadacitinib
Metabolizing enzyme substrate
DG01644 CYP2D6 substrate
DG02829 Upadacitinib
DG01633 CYP3A/CYP3A4 substrate
DG02913 CYP3A4 substrate
DG02829 Upadacitinib